CB2 cannabinoid receptors on peripheral sensory neurons, not immune cells, are required for the anti-pain effects of the CB2 agonist LY2828360 in inflammatory pain.
Pain researchers, pharmacologists developing cannabinoid therapeutics, and neuroscientists studying the endocannabinoid system.
Neuronal CB2 requiredfor anti-pain effects — efficacy was absent in sensory neuron CB2 knockouts but preserved in immune cell CB2 knockouts
What the researchers found
The anti-allodynic efficacy of CB2 agonist LY2828360 was absent in mice lacking CB2 receptors on peripheral sensory neurons but preserved in mice lacking CB2 on immune cells, establishing neuronal CB2 as the therapeutic target.
Why it matters
Identifying the exact cell type responsible for CB2-mediated pain relief enables more targeted drug development and helps explain why CB2 agonists work without the side effects of CB1 activation.
The numbers in context
LY2828360 at 10 mg/kg reversed carrageenan-induced mechanical allodynia. Local paw injection (30 μg) also reversed allodynia in control but not sensory neuron CB2 knockout mice. LY2828360 reduced IL-1β and IL-10 mRNA in paw skin.
How the study worked
Preclinical study using global CB1 and CB2 knockout mice and conditional knockout mice lacking CB2 in peripheral sensory neurons or microglia/macrophages. Carrageenan-induced inflammatory pain model tested in both sexes.
Who was studied
Female and male mice with various CB2 receptor conditional knockouts in a carrageenan-induced inflammatory pain model.
What this study cannot tell us
Mouse models may not fully translate to human pain pathways. Conditional knockout systems may have incomplete deletion. Single inflammatory pain model tested.
How to read the evidence
Rigorous preclinical study using multiple genetic controls; strong mechanistic evidence but requires human translation.
When this study was published
Recent preclinical research advancing understanding of CB2 pain mechanisms.
The bigger picture
This study provides mechanistic clarity for CB2-targeted pain therapeutics, demonstrating that the analgesic effects operate through sensory neurons rather than immune modulation, which could guide the development of next-generation pain medications.
Replication
Builds on prior work by same group on neuropathic pain; inflammatory pain model adds new evidence.
Funding
Not specified in abstract
Conflicts of interest
Not specified in abstract
Questions still open
- Could peripheral-selective CB2 agonists provide pain relief with even fewer central nervous system side effects?
- Does the neuronal CB2 mechanism apply to chronic pain conditions beyond carrageenan-induced inflammation?
Read the original research
Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.
Neuropharmacology, 237, 109601
Citation
Guenther, Kelsey G; Xu, Zhili; Romero, Julian; Hillard, Cecilia J; Mackie, Ken; Hohmann, Andrea G. (2023). Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.. Neuropharmacology, 237, 109601. https://doi.org/10.1016/j.neuropharm.2023.109601